Terms: = Colorectal cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S AND Treatment
110 results:
1. Multigene Panel Next-Generation Sequencing Techniques in the Management of Patients with Metastatic colorectal Carcinoma: The Way Forward for Personalized treatment? A Single-Center Experience.
Matteucci L; Sullo FG; Gallio C; Esposito L; Muratore M; Rapposelli IG; Calistri D; Petracci E; Rengucci C; Capelli L; Chiadini E; Ulivi P; Passardi A; Bittoni A
Int J Mol Sci; 2024 Oct; 25(20):. PubMed ID: 39456850
[TBL] [Abstract] [Full Text] [Related]
2. Integrative Omics Uncovers Low Tumorous Magnesium Content as A Driver Factor of colorectal cancer.
Zhang R; Hu M; Liu Y; Li W; Xu Z; He S; Lu Y; Gong Y; Wang X; Hai S; Li S; Qi S; Li Y; Shu Y; Du D; Zhang H; Xu H; Zhou Z; Lei P; Chen HN; Dai L
Genomics Proteomics Bioinformatics; 2024 Oct; 22(4):. PubMed ID: 39052867
[TBL] [Abstract] [Full Text] [Related]
3. DB-1310, an ADC comprised of a novel anti-her3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of her3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
4. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
[TBL] [Abstract] [Full Text] [Related]
5. Endorobotic submucosal dissection of rectal lesions using the single port robot DaVinci-SP: initial experience of the first 10 cases.
Ozgur I; Cheong JY; Liska D; Holubar S; Valante MA; Steele SR; Gorgun E
ANZ J Surg; 2024 Apr; 94(4):691-696. PubMed ID: 38012087
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract] [Full Text] [Related]
7. Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous colorectal Adenocarcinoma Cells.
Kuracha MR; Govindarajan V; Loggie BW; Tobi M; McVicker BL
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569713
[TBL] [Abstract] [Full Text] [Related]
8. Disparities in geospatial patterns of cancer care within urban counties and structural inequities in access to oncology care.
McGee-Avila JK; Richmond J; Henry KA; Stroup AM; Tsui J
Health Serv Res; 2023 Aug; 58 Suppl 2(Suppl 2):152-164. PubMed ID: 37208901
[TBL] [Abstract] [Full Text] [Related]
9. MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the erbb3/AKT axis.
Candiello E; Reato G; Verginelli F; Gambardella G; D Ambrosio A; Calandra N; Orzan F; Iuliano A; Albano R; Sassi F; Luraghi P; Comoglio PM; Bertotti A; Trusolino L; Boccaccio C
Mol Oncol; 2023 Jul; 17(7):1280-1301. PubMed ID: 36862005
[TBL] [Abstract] [Full Text] [Related]
10. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract] [Full Text] [Related]
11. PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and erbb3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Propper DJ; Gao F; Saunders MP; Sarker D; Hartley JA; Spanswick VJ; Lowe HL; Hackett LD; Ng TT; Barber PR; Weitsman GE; Pearce S; White L; Lopes A; Forsyth S; Hochhauser D
Br J Cancer; 2023 Jan; 128(2):245-254. PubMed ID: 36352028
[TBL] [Abstract] [Full Text] [Related]
12. Pertuzumab Plus Trastuzumab in Patients With colorectal cancer With
Gupta R; Meric-Bernstam F; Rothe M; Garrett-Mayer E; Mangat PK; D'Andre S; Ahn ER; O'Lone R; Halabi S; Grantham GN; Schilsky RL
JCO Precis Oncol; 2022 Oct; 6():e2200306. PubMed ID: 36315917
[TBL] [Abstract] [Full Text] [Related]
13. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract] [Full Text] [Related]
14. MiR-323a regulates erbb3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer.
Zhang Y; Liang S; Xiao B; Hu J; Pang Y; Liu Y; Yang J; Ao J; Wei L; Luo X
Cell Death Dis; 2022 Mar; 13(3):256. PubMed ID: 35319011
[TBL] [Abstract] [Full Text] [Related]
15. Mechanisms of GZ17-6.02 resistance.
Booth L; West C; Von Hoff D; Dent P
Anticancer Drugs; 2022 Jun; 33(5):415-423. PubMed ID: 35276694
[TBL] [Abstract] [Full Text] [Related]
16. Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in colorectal cancer.
Rau A; Janssen N; Kühl L; Sell T; Kalmykova S; Mürdter TE; Dahlke MH; Sers C; Morkel M; Schwab M; Kontermann RE; Olayioye MA
Mol Cancer Ther; 2022 May; 21(5):799-809. PubMed ID: 35247930
[TBL] [Abstract] [Full Text] [Related]
17. Diagnosis and treatment of ERBB2-Positive Metastatic colorectal cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract] [Full Text] [Related]
18. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Berlin J; Tolcher AW; Ding C; Whisenant JG; Horak ID; Wood DL; Nadler PI; Hansen UH; Lantto J; Skartved NJØ; Pedersen MW; Patnaik A
Invest New Drugs; 2022 Jun; 40(3):586-595. PubMed ID: 35113285
[TBL] [Abstract] [Full Text] [Related]
19. Anti‑her3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract] [Full Text] [Related]
20. Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of colorectal cancer Cells.
El Hallal R; Lyu N; Wang Y
Molecules; 2021 Jan; 26(3):. PubMed ID: 33499047
[TBL] [Abstract] [Full Text] [Related]
[Next]
